Preclinical models of BCL2 expressing HR + /HER2− cancer cells shows enhanced apoptosis with the use of a BCL2 inhibitor ABT-199 (venetoclax) in combination with tamoxifen136, as well as triple therapy of venetoclax with fulvestrant and palbociclib137. This evidence concerns the gene BCL2 and cancer.